Jasper Therapeutics (JSPR) Change in Receivables (2023)
Jasper Therapeutics (JSPR) posted quarterly Change in Receivables of -$663000.0 for Q1 2023.
Jasper Therapeutics (JSPR) Change in Receivables (2023) Analysis & Trends
Jasper Therapeutics' Change in Receivables history runs 1 years deep, the most recent figure standing at -$663000.0 for Q1 2023.
- In Q1 2023, Change in Receivables changed N/A year-over-year to -$663000.0; the TTM figure through Dec 2023 stood at -$663000.0 (changed N/A YoY), while the FY2023 annual figure was -$663000.0, down 200.0% from the prior year.
- Change in Receivables for Q1 2023 stood at -$663000.0.
- The five-year high for Change in Receivables was -$663000.0 in Q1 2023, with the low at -$663000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | - |
| 10 | Jasper Therapeutics | 20.46 Mn | 20.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -663,000.00 |
| Mar 31, 2023 | -663,000.00 |